INCY Incyte
- 52.380
- +0.700+1.35%
Incyte News
Truist Financial Reaffirms Their Buy Rating on Incyte (INCY)
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Incyte's Strategic Acquisition and Promising Pipeline Secure Buy Rating
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates From VRTX
Express News | Incyte : Oppenheimer Cuts Target Price to $84 From $92
Oppenheimer Sticks to Its Buy Rating for Incyte (INCY)
Incyte Price Target Cut to $84.00/Share From $92.00 by Oppenheimer
Incyte Price Target Cut to $84.00/Share From $92.00 by Oppenheimer
Incyte Is Maintained at Outperform by Oppenheimer
Incyte Is Maintained at Outperform by Oppenheimer
Express News | Oppenheimer Maintains Outperform on Incyte, Lowers Price Target to $84
Truist Financial Keeps Their Buy Rating on Incyte (INCY)
Incyte Acquisition Strategy and Drug Pipeline Evaluation: A Hold Recommendation
Express News | Incyte Corp : Oppenheimer Cuts Target Price to $84 From $93
Incyte's Strategic Acquisition: A Premature and Costly Move Amid Patent Cliff Concerns
Incyte (INCY) Gets a Buy From Piper Sandler
Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends
Tuesday, Incyte Corporation (NASDAQ:INCY) agreed to acquire Escient Pharmaceuticals for $750 million.Escient's pipeline includes EP262, a small molecule antagonist of Mas-related G protein-coupled rec
Peeling Back The Layers: Exploring Incyte Through Analyst Insights
Across the recent three months, 10 analysts have shared their insights on Incyte (NASDAQ:INCY), expressing a variety of opinions spanning from bullish to bearish.The table below provides a concise ove
Incyte (INCY) Earnings Expected to Grow: Should You Buy?
Incyte (INCY) to Report Q1 Earnings: What's in the Cards?
Incyte To Buy Privately Held Escient Pharma
Incyte Initiated at Neutral by Cantor Fitzgerald
Incyte Initiated at Neutral by Cantor Fitzgerald
Analysis
Price Target
No Data
